An interview with Izumo Seigo (出雲正剛), Global Head of Takeda Pharmaceutical Company's Regenerative Medicine Unit, outlined T-CiRA's distinctiveness and future prospects. Under a comprehensive collaboration framework involving an investment of ¥20 billion over 10 years, the program aims to begin clinical trials for 1 product within 5 years.
In December 2015, Takeda Pharmaceutical Company Limited launched a joint research program with Kyoto University's Center for iPS Cell Research and Application (CiRA) and has been advancing the Takeda-CiRA Joint Program for iPS Cell Applications (T-CiRA). The comprehensive collaboration framework involves an investment of ¥20 billion over 10 years, and 8 projects are currently underway.
Izumo Seigo (出雲正剛), Global Head of Takeda Pharmaceutical Company's Regenerative Medicine Unit, explained T-CiRA's distinctiveness and its future objectives. He particularly highlighted the program's efforts toward the clinical application of regenerative medicine, including gene therapy and cell therapies.
As a future objective, the program has stated that it aims to begin clinical trials for 1 product within 5 years. This can be read as including the acceleration of research and development through the T-CiRA framework and the strengthening of collaboration between companies and research institutions.
This article is a summary of a paid article, and details of related initiatives by other companies and additional progress are not included in the article.